https://orcid.org/0000-0002-6429-5149
Population-scale genomics (N = 937 939) allowed assembly of a large FVL/PTGM double-heterozygous cohort while mitigating ascertainment bias.
FVL/PTGM DH appeared to be more common than FVL homozygosity and conferred a similar risk of venous thrombosis.
Abstract
The factor V Leiden (FVL; rs6025) and prothrombin G20210A (PTGM; rs1799963) polymorphisms are 2 of the most well-studied genetic risk factors for venous thromboembolism (VTE). However, double heterozygosity (DH) for FVL and PTGM remains poorly understood, with previous studies showing marked disagreement regarding thrombosis risk conferred by the DH genotype. Using multidimensional data from the UK Biobank (UKB) and FinnGen biorepositories, we evaluated the clinical impact of DH carrier status across 937 939 individuals. We found that 662 participants (0.07%) were DH carriers. After adjustment for age, sex, and ancestry, DH individuals experienced a markedly elevated risk of VTE compared with wild-type individuals (odds ratio [OR] = 5.24; 95% confidence interval [CI], 4.01-6.84; P = 4.8 × 10−34), which approximated the risk conferred by FVL homozygosity. A secondary analysis restricted to UKB participants (N = 445 144) found that effect size estimates for the DH genotype remained largely unchanged (OR = 4.53; 95% CI, 3.42-5.90; P < 1 × 10−16) after adjustment for commonly cited VTE risk factors, such as body mass index, blood type, and markers of inflammation. In contrast, the DH genotype was not associated with a significantly higher risk of any arterial thrombosis phenotype, including stroke, myocardial infarction, and peripheral artery disease. In summary, we leveraged population-scale genomic data sets to conduct, to our knowledge, the largest study to date on the DH genotype and were able to establish far more precise effect size estimates than previously possible. Our findings indicate that the DH genotype may occur as frequently as FVL homozygosity and may confer a similarly increased risk of VTE.
References
1.
Bertina
RM
, Koeleman
BP
, Koster
T
, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C
. Nature
. 1994
;369
(6475
):64
-67
.2.
Poort
SR
, Rosendaal
FR
, Reitsma
PH
, Bertina
RM
. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
. Blood
. 1996
;88
(10
):3698
-3703
.3.
Dahlback
B
, Carlsson
M
, Svensson
PJ
. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C
. Proc Natl Acad Sci U S A
. 1993
;90
(3
):1004
-1008
.4.
Dahlback
B
, Hildebrand
B
. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V
. Proc Natl Acad Sci U S A
. 1994
;91
(4
):1396
-1400
.5.
Leroyer
C
, Mercier
B
, Escoffre
M
, Férec
C
, Mottier
D
. Factor V Leiden prevalence in venous thromboembolism patients
. Chest
. 1997
;111
(6
):1603
-1606
.6.
Bauduer
F
, Lacombe
D
. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics
. Mol Genet Metab
. 2005
;86
(1-2
):91
-99
.7.
Cattaneo
M
, Chantarangkul
V
, Taioli
E
, Santos
JH
, Tagliabue
L
. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels
. Thromb Res
. 1999
;93
(1
):1
-8
.8.
De Stefano
V
, Chiusolo
P
, Paciaroni
K
, Leone
G
. Epidemiology of factor V Leiden: clinical implications
. Semin Thromb Hemost
. 1998
;24
(4
):367
-379
.9.
Dentali
F
, Ageno
W
, Bozzato
S
, et al. Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a meta-analysis of the literature
. J Thromb Haemost
. 2012
;10
(4
):732
-737
.10.
Rosendaal
FR
, Reitsma
PH
. Genetics of venous thrombosis
. J Thromb Haemost
. 2009
;7
(suppl 1
):301
-304
.11.
Hessner
MJ
, Luhm
RA
, Pearson
SL
, Endean
DJ
, Friedman
KD
, Montgomery
RR
. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR
. Thromb Haemost
. 1999
;81
(5
):733
-738
.12.
Pepe
G
, Rickards
O
, Vanegas
OC
, et al. Prevalence of factor V Leiden mutation in non-European populations
. Thromb Haemost
. 1997
;77
(2
):329
-331
.13.
Rees
DC
, Cox
M
, Clegg
JB
. World distribution of factor V Leiden
. Lancet
. 1995
;346
(8983
):1133
-1134
.14.
Klarin
D
, Busenkell
E
, Judy
R
, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease
. Nat Genet
. 2019
;51
(11
):1574
-1579
.15.
Manderstedt
E
, Lind-Hallden
C
, Hallden
C
, et al. Classic thrombophilias and thrombotic risk among middle-aged and older adults: a population-based cohort study
. J Am Heart Assoc
. 2022
;11
(4
):e023018
.16.
Lindstrom
S
, Wang
L
, Smith
EN
, et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
. Blood
. 2019
;134
(19
):1645
-1657
.17.
De Stefano
V
, Martinelli
I
, Mannucci
PM
, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
. N Engl J Med
. 1999
;341
(11
):801
-806
.18.
Emmerich
J
, Rosendaal
FR
, Cattaneo
M
, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism
. Thromb Haemost
. 2001
;86
(3
):809
-816
.19.
Simone
B
, De Stefano
V
, Leoncini
E
, et al. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls
. Eur J Epidemiol
. 2013
;28
(8
):621
-647
.20.
Martinelli
I
, Bucciarelli
P
, Margaglione
M
, De Stefano
V
, Castaman
G
, Mannucci
PM
. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both
. Br J Haematol
. 2000
;111
(4
):1223
-1229
.21.
Luxembourg
B
, Henke
F
, Kirsch-Altena
A
, Sachs
U
, Kemkes-Matthes
B
. Impact of double heterozygosity for Factor V Leiden and prothrombin G20210A on the thrombotic phenotype
. Thromb Res
. 2021
;200
:121
-127
.22.
Segal
JB
, Brotman
DJ
, Necochea
AJ
, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review
. JAMA
. 2009
;301
(23
):2472
-2485
.23.
Zoller
B
, Svensson
PJ
, Dahlback
B
, Hillarp
A
. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families
. Blood
. 1998
;91
(6
):2210
-2211
.24.
Bycroft
C
, Freeman
C
, Petkova
D
, et al. The UK Biobank resource with deep phenotyping and genomic data
. Nature
. 2018
;562
(7726
):203
-209
.25.
Kurki
MI
, Karjalainen
J
, Palta
P
, et al. FinnGen provides genetic insights from a well-phenotyped isolated population
. Nature
. 2023
;613
(7944
):508
-518
.26.
Jurgens
SJ
, Choi
SH
, Morrill
VN
, et al. Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank
. Nat Genet
. 2022
;54
(3
):240
-250
.27.
Jurgens
SJ
, Pirruccello
JP
, Choi
SH
, et al. Adjusting for common variant polygenic scores improves yield in rare variant association analyses
. Nat Genet
. 2023
;55
(4
):544
-548
.28.
Wang
X
. Firth logistic regression for rare variant association tests
. Front Genet
. 2014
;5
:187
.29.
Heinze
G
, Schemper
M
. A solution to the problem of separation in logistic regression
. Stat Med
. 2002
;21
(16
):2409
-2419
.30.
Ornstein
DL
, Cushman
M
. Cardiology patient page. Factor V Leiden
. Circulation
. 2003
;107
(15
):e94
-e97
.31.
Ridker
PM
, Miletich
JP
, Hennekens
CH
, Buring
JE
. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
. JAMA
. 1997
;277
(16
):1305
-1307
.32.
Limdi
NA
, Beasley
TM
, Allison
DB
, Rivers
CA
, Acton
RT
. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy
. Blood Cells Mol Dis
. 2006
;37
(2
):100
-106
.33.
Thompson
DJ
, Wells
D
, Selzam
S
, et al. UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits
. medRxiv
. Preprint posted online 16 June 2022
.34.
Warny
M
, Helby
J
, Birgens
HS
, Bojesen
SE
, Nordestgaard
BG
. Arterial and venous thrombosis by high platelet count and high hematocrit: 108 521 individuals from the Copenhagen General Population Study
. J Thromb Haemost
. 2019
;17
(11
):1898
-1911
.35.
Carobbio
A
, Thiele
J
, Passamonti
F
, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
. Blood
. 2011
;117
(22
):5857
-5859
.36.
Middeldorp
S
. Factor V Leiden and activated protein C resistance. In: Post
TW
, eds. UptoDate
. Wolters Kluwer
; 2023
.37.
Couturaud
F
, Kearon
C
, Leroyer
C
, et al. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden
. Thromb Haemost
. 2006
;96
(6
):744
-749
.38.
Mean
M
, Breakey
N
, Stalder
O
, et al. Thrombophilia and outcomes of venous thromboembolism in older patients
. Res Pract Thromb Haemost
. 2023
;7
(1
):100015
.39.
Ye
Z
, Liu
EH
, Higgins
JP
, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls
. Lancet
. 2006
;367
(9511
):651
-658
.40.
Chiasakul
T
, De Jesus
E
, Tong
J
, et al. Inherited thrombophilia and the risk of arterial ischemic stroke: a systematic review and meta-analysis
. J Am Heart Assoc
. 2019
;8
(19
):e012877
.41.
Klarin
D
, Lynch
J
, Aragam
K
, et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program
. Nat Med
. 2019
;25
(8
):1274
-1279
.42.
May
JE
, Moll
S
. Unexplained arterial thrombosis: approach to diagnosis and treatment
. Hematology Am Soc Hematol Educ Program
. 2021
;2021
(1
):76
-84
.43.
Fry
A
, Littlejohns
TJ
, Sudlow
C
, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population
. Am J Epidemiol
. 2017
;186
(9
):1026
-1034
.44.
Gohil
R
, Peck
G
, Sharma
P
. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls
. Thromb Haemost
. 2009
;102
(2
):360
-370
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal